CLDX (Celldex Therapeutics) Insider Ownership: 8.52 % (As of Jul. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLDX Celldex Therapeutics Inc CLDX
57 GF Score
Price $35.07
GF Value $7.32
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Celldex Therapeutics Insider Ownership?

Celldex Therapeutics CLDX -1.00% 57 Insider Ownership is 8.52 % as of Jul. 24, 2026. GuruFocus rates CLDX with a GF Score™ of 57/100 and a GF Value™ of $7.32 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Celldex Therapeutics's insider ownership is 8.52%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Celldex Therapeutics's Institutional Ownership is 98.39%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Celldex Therapeutics's Float Percentage Of Total Shares Outstanding is 84.25%.

Celldex Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Celldex Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celldex Therapeutics Insider Ownership Chart

Celldex Therapeutics Historical Data

The historical data trend for Celldex Therapeutics can be seen below:

2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30
Insider Ownership 10.04 10.04 10.04 10.04 10.04 10.04 10.07 10.04 8.52 8.52
CLDX
57GF Score
Celldex Therapeutics Inc CLDX
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celldex Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 8.52 % mean?
Celldex Therapeutics (CLDX) has a Insider Ownership of 8.52 % as of Jul. 24, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Celldex Therapeutics and its competitors.
Is Celldex Therapeutics' Insider Ownership too high?
Celldex Therapeutics' current Insider Ownership is 8.52 %. Overall, Celldex Therapeutics has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celldex Therapeutics' Insider Ownership compare to TARS and KLRA?
Celldex Therapeutics' Insider Ownership of 8.52 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Celldex Therapeutics and its competitors. Celldex Therapeutics's current Insider Ownership is 8.52 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celldex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Celldex Therapeutics (CLDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.32, compared to a current price of $35.07 — trading 379% above its estimated fair value. The current Insider Ownership is 8.52 %. Celldex Therapeutics' overall GF Score™ is 57/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Celldex Therapeutics (CLDX), the current Insider Ownership is 8.52 % as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celldex Therapeutics (CLDX) Overvalued in 2026?

Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued. The current stock price of $35.07 is trading 379% above its estimated GF Value™ of $7.32. GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.

Key valuation signals for CLDX:

  • Insider Ownership: 8.52 %
  • GF Value™: $7.32 vs. price of $35.07 (379% above fair value)
  • GF Score™: 57/100 with 8 warning signs

No single metric tells the full story. See the CLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celldex Therapeutics Business Description

Other Exchanges TCE2:Germany
Address 53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
57GF Score

Get the complete analysis for CLDX

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.07
Price
$7.32
GF Value